Advances in clinical trial design: Weaving tomorrow’s TB treatments

• Christian Lienhardt ,

  * E-mail: christian.lienhardt@ird.fr

  Affiliation Unité Mixte Internationale TransVIHMI, UMI 233 IRD–U1175 INSERM—Université de Montpellier, Institut de Recherche pour le Développement (IRD), Montpellier, France

  http://orcid.org/0000-0003-0233-893X

  ⨯
• Andrew Nunn,

  Affiliation MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, United Kingdom

  http://orcid.org/0000-0002-9158-4595

  ⨯
• Richard Chaisson,

  Affiliation Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, United States of America

  ⨯
• Andrew A. Vernon,

  Affiliation Division of TB Elimination, National Center for HIV, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

  http://orcid.org/0000-0003-1105-8534

  ⨯
• Matteo Zignol,

  Affiliation Global TB Programme, World Health Organization, Geneva, Switzerland

  ⨯
• Payam Nahid,

  Affiliation UCSF Center for Tuberculosis and Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, California, United States of America

  http://orcid.org/0000-0003-2811-1311

  ⨯
• Eric Delaporte,

  Affiliation Unité Mixte Internationale TransVIHMI, UMI 233 IRD–U1175 INSERM—Université de Montpellier, Institut de Recherche pour le Développement (IRD), Montpellier, France

  ⨯
• Tereza Kasaeva

  Affiliation Global TB Programme, World Health Organization, Geneva, Switzerland

  http://orcid.org/0000-0002-3986-1460

  ⨯